Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2020 3
2021 9
2022 16
2023 12
2024 39
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma.
Fallah J, Heiss BL, Joeng HK, Weinstock C, Gao X, Pierce WF, Chukwurah B, Bhatnagar V, Fiero MH, Amiri-Kordestani L, Pazdur R, Kluetz PG, Suzman DL. Fallah J, et al. Clin Cancer Res. 2024 Nov 15;30(22):5003-5008. doi: 10.1158/1078-0432.CCR-24-1199. Clin Cancer Res. 2024. PMID: 39248780 Clinical Trial.
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.
Barbato MI, Bradford D, Ren Y, Aungst SL, Miller CP, Pan L, Zirkelbach JF, Li Y, Bi Y, Fan J, Grimstein M, Dorff SE, Amatya AK, Mishra-Kalyani PS, Scepura B, Schotland P, Udoka O, Ojofeitimi I, Leighton JK, Rahman NA, Pazdur R, Singh H, Kluetz PG, Drezner N. Barbato MI, et al. Clin Cancer Res. 2024 Aug 15;30(16):3364-3370. doi: 10.1158/1078-0432.CCR-24-0949. Clin Cancer Res. 2024. PMID: 38875108 Clinical Trial.
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
Fusco MJ, Casak SJ, Mushti SL, Cheng J, Christmas BJ, Thompson MD, Fu W, Wang H, Yoon M, Yang Y, Moore JN, Bi Y, Nan Y, Long CE, Auth D, Rahman NA, Tang S, Pazdur R, Fashoyin-Aje LA, Kluetz PG, Lemery SJ. Fusco MJ, et al. Clin Cancer Res. 2024 Aug 1;30(15):3100-3104. doi: 10.1158/1078-0432.CCR-24-0281. Clin Cancer Res. 2024. PMID: 38809262 Clinical Trial.
Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent.
Totsch SK, Ishizuka AS, Kang KD, Gary SE, Rocco A, Fan AE, Zhou L, Valdes PA, Lee S, Li J, Peruzzotti-Jametti L, Blitz S, Garliss CM, Johnston JM, Markert JM, Lynn GM, Bernstock JD, Friedman GK. Totsch SK, et al. Mol Cancer Ther. 2024 Sep 4;23(9):1273-1281. doi: 10.1158/1535-7163.MCT-23-0873. Mol Cancer Ther. 2024. PMID: 38710101
Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models.
Jiao Y, Yan J, Sutaria DS, Lu P, Vicchiarelli M, Reyna Z, Ruiz-Delgado J, Burk E, Moon E, Shah NR, Spellberg B, Bonomo RA, Drusano GL, Louie A, Luna BM, Bulitta JB. Jiao Y, et al. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0139423. doi: 10.1128/aac.01394-23. Epub 2024 Jan 30. Antimicrob Agents Chemother. 2024. PMID: 38289076 Free PMC article.
80 results